Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies-Reference-Cited by-同舟云学术

Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies

Published:2022-06-28 Issue:3 Volume:13 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Boutin Marianne¹²,Vézina Dani¹^ORCID,Ding Shilei¹,Prévost Jérémie¹²,Laumaea Annemarie¹²,Marchitto Lorie¹²,Anand Sai Priya³,Medjahed Halima¹,Gendron-Lepage Gabrielle¹,Bourassa Catherine¹,Goyette Guillaume¹,Clark Andrew⁴,Richard Jonathan¹²,Finzi Andrés¹²³^ORCID

Affiliation:

1. Centre de Recherche du CHUM (CRCHUM), Montreal, Quebec, Canada

2. Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, Quebec, Canada

3. Department of Microbiology and Immunology, McGill University, Montreal, Quebec, Canada

4. ViiV Healthcare, Global Medical Affairs, Middlesex, United Kingdom

Abstract

FDA-approved fostemsavir, the prodrug for the active moiety small molecule temsavir (GSK 2616713 [formally BMS-626529]), acts as an attachment inhibitor by targeting the HIV-1 envelope (Env) and preventing CD4 interaction. Temsavir also stabilizes Env in its “closed,” functional state 1 conformation, which represents an ideal target for broadly neutralizing antibodies (bNAbs).

Funder

Canadian Institutes of Health Research

Gouvernement du Canada | Canadian Institutes of Health Research

Canada Foundation for Innovation

Canada Research Chairs

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mbio.00577-22

Reference24 articles.